Lonza jumps 3.8% after Sfr2.25bn rights issue wins approval from shareholders
GlobalCapital, is part of the Delinian Group, DELINIAN (GLOBALCAPITAL) LIMITED, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 15236213
Copyright © DELINIAN (GLOBALCAPITAL) LIMITED and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Lonza jumps 3.8% after Sfr2.25bn rights issue wins approval from shareholders

Shares in Lonza, the Swiss pharmaceutical company, closed 3.8% higher on Wednesday after it launched its Sfr2.25bn rights issue to partly finance its acquisition of Capsugel from KKR, having secured approval from its shareholders at its annual general meeting on Tuesday.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login
Gift this article